z-logo
Premium
Diabetic kidney transplant recipients: Impaired infection control and increased alloreactivity
Author(s) -
Schachtner Thomas,
Stein Maik,
Reinke Petra
Publication year - 2017
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.12986
Subject(s) - medicine , immunosuppression , diabetes mellitus , transplantation , elispot , tacrolimus , immunology , kidney transplantation , gastroenterology , immune system , t cell , endocrinology
Background Post‐transplantation diabetes mellitus ( PTDM ) has been associated with inferior patient and allograft outcomes. However, previous studies did not identify differences in infection control and alloreactivity. Methods We studied 449 kidney transplant recipients ( KTR s) between 2005 and 2013. Fifty (11.1%) KTR s were diagnosed with PTDM and 60 (13.4%) KTR s with pre‐existing diabetes. Samples were collected pretransplantation, at +1, +2, +3 months post‐transplantation. CMV specific and alloreactive T cells were quantified by interferon‐γ Elispot assay. Lymphocyte subpopulations were quantified by flow cytometry. Results Upon multivariate analysis, age, obesity, and the use of tacrolimus increased the risk of PTDM ( P <.05). KTR s with pre‐existing diabetes/ PTDM showed higher rates of sepsis ( P <.01). Total CD 3+ and CD 4+ T cell counts were significantly lower in KTR s with PTDM /pre‐existing diabetes post‐transplantation ( P <.05). No differences were observed for CMV ‐specific T cells between any group ( P >.05). KTR s developing PTDM showed increased frequencies of alloreactive T‐cells post‐transplantation ( P <.05). Conclusions Our results suggest higher rates of infection in KTR s with pre‐existing diabetes/ PTDM that may be attributed to impaired overall immunity. Higher frequencies of alloreactive T cells contribute to inferior long‐term outcomes. As acute rejection, but not pre‐existing diabetes/ PTDM , was associated with inferior allograft survival and function, maintaining adequate immunosuppression to prevent rejection seems important.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here